Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enhancing immunogenicity by CpG DNA.

Weiwen Jiang1, David S Pisetsky

  • 1Durham VA Medical Center, 508 Fulton Street, PO Box 151G, Durham, NC 27705, USA.

Current Opinion in Molecular Therapeutics
|May 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Making Artificial Intelligence More Intelligent and Less Artificial for Rheumatology: A Vision for Empathy, Education, Equity, and Ethics.

Arthritis care & research·2026
Same author

The influence of nuclear antigen form on complement activation by systemic lupus erythematosus antinuclear antibody immune complexes determined by a novel immunocapture assay.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

VACSEN: A Visualization Approach for Noise Awareness in Quantum Computing.

IEEE transactions on visualization and computer graphics·2026
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

A Quantum Framework for Protein Binding-Site Structure Prediction on Utility-Level Quantum Processors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Z-GENIE: a user-friendly R/Shiny resource for predicting Z-DNA forming regions in DNA.

BMC genomics·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Bacterial CpG DNA stimulates immune responses by interacting with toll-like receptor 9, acting as a potent adjuvant. This DNA holds promise for therapeutic applications in cancer and allergy treatments.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Bacterial DNA and CpG oligonucleotides stimulate immune responses.
  • Unmethylated CpG dinucleotides are key immune stimulators.
  • CpG DNA has potential as an immunogenicity enhancer.

Purpose of the Study:

  • To explore the immune-stimulating properties of CpG DNA.
  • To investigate the signaling pathways involved in CpG DNA immune activation.
  • To highlight the therapeutic potential of CpG DNA.

Main Methods:

  • Interaction of CpG DNA with toll-like receptor 9 (TLR9).
  • Activation via myeloid differentiation primary response gene 88 (MyD88)-dependent pathway.
  • Analysis of induced cytokine milieu and T-helper cell responses.

Related Experiment Videos

Main Results:

  • CpG DNA activates immune cells through TLR9 and MyD88.
  • CpG DNA induces cytokines that promote T-helper cell responses.
  • CpG DNA acts as an effective adjuvant.

Conclusions:

  • CpG DNA is a potent immune stimulant and adjuvant.
  • CpG DNA demonstrates protective effects against pathogens in animal models.
  • CpG DNA has therapeutic applications in cancer and allergy.